Suppliers and packagers for EVOMELA

EVOMELA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Acrotech Biopharma	EVOMELA	melphalan hydrochloride	POWDER;INTRAVENOUS	207155	NDA	Acrotech Biopharma Inc	72893-001-01	1 VIAL in 1 CARTON (72893-001-01) / 20 mL in 1 VIAL	2016-03-31

Suppliers for the Pharmaceutical Drug: EVOMELA

Last updated: July 31, 2025

Introduction

EVOMELA (melphalan hydrochloride for injection) is a chemotherapeutic agent primarily prescribed for conditioning in hematopoietic stem cell transplantation, particularly for multiple myeloma and lymphoma treatments. As an injectable alkylating agent, EVOMELA’s procurement involves a network of specialized suppliers, including manufacturers, distributors, and authorized resellers. Understanding the supply landscape is critical for healthcare providers, procurement departments, and industry stakeholders aiming to ensure drug availability, regulatory compliance, and cost management.

Manufacturers of EVOMELA

Evoltra LLC / Clinigen Group

The primary manufacturer behind EVOMELA is Evoltra LLC, a subsidiary of Clinigen Group. The drug was developed to address limitations associated with oral melphalan therapy, offering a more predictable pharmacokinetic profile via intravenous formulation. Evoltra LLC is responsible for the manufacturing, quality control, and distribution of EVOMELA.

• Manufacturing facilities: Located within the United States, FDA-approved, adhering to Good Manufacturing Practices (GMP).
• Regulatory approval: EVOMELA received FDA approval in 2018, with subsequent approvals in various international markets (e.g., Europe, Japan).

Other Potential Manufacturers

As of now, EVOMELA appears to be exclusively produced by Evoltra LLC. No other manufacturers publicly market generic versions substantially, owing partly to patent protections and proprietary manufacturing processes. However, ongoing research into biosimilars and generics may alter this landscape in the future.

Authorized Distributors and Supply Chain Partners

Clinigen Group’s Distribution Network

Clinigen’s global distribution platform ensures supply continuity across multiple regions:

• United States: Direct distribution to hospitals and providers through Clinigen’s specialty pharmacy network.
• Europe and Asia: Collaboration with regional distributors compliant with local regulatory requirements.
• Regional distributors are typically authorized by Clinigen, ensuring product integrity, traceability, and regulatory compliance.

Major Distribution Partners

• McKesson Corporation: Often acts as an intermediary distributor for specialty injectables in North America.
• Cardinal Health: Participates in distributing EVOMELA in select regions, leveraging their established hospital supply chains.
• Local Regional Distributors: Hospitals often acquire EVOMELA through regional pharmaceutical wholesalers with specific agreements with Clinigen.

Supply Chain Considerations

The supply chain for EVOMELA is tightly regulated, given the cytotoxic nature of the drug:

• Cold chain management: Ensures product stability.
• Traceability: Tracks lot numbers from manufacturing to administration.
• Regulatory compliance: Distributors operate under strict licensing aligned with FDA, EMA, or other local regulatory bodies.

Market Dynamics and Availability

Global Accessibility

• United States: Widely accessible through hospital pharmacies, oncologists, and specialty pharmacies.
• Europe: Approved and available via authorized distributors; procurement often coordinated through regional healthcare systems.
• Asia and Emerging Markets: Availability varies; tends to be limited to major cancer treatment centers with established supply arrangements.

Supply Constraints and Challenges

• Manufacturing capacity: Limited by the specialized nature of the production process and GMP requirements.
• Regulatory delays: Can restrict timely approval or importation into certain markets.
• Global demand: Growing prevalence of hematological malignancies increases demand, potentially impacting stock levels.

Key Considerations for Procurement and Supply Chain Security

• Supplier Verification: Ensure procurement from authorized distributors to guarantee product quality and legal compliance.
• Inventory Management: Due to high oncological demand, maintaining optimal stock levels is crucial to prevent shortages.
• Regulatory Vigilance: Monitor regional approvals and updates, especially if considering imports or cross-border procurement.
• Cost Control: Price negotiations with distributors and understanding of regional pricing strategies are vital for healthcare systems.

Future Outlook

The pipeline for EVOMELA's supply includes potential expansion through:

• Generic manufacturing: Pending patent expirations, which could increase supply and reduce costs.
• Alternate formulations: Research into oral or other delivery methods might diversify supply sources.
• Regional manufacturing: Localized production plants could mitigate current supply constraints and lead times.

Key Takeaways

• EVOMELA is primarily manufactured by Evoltra LLC, under Clinigen Group, with distribution through a global network of authorized partners.
• The drug’s specialty nature and regulatory requirements create a tightly managed supply chain emphasizing product integrity and traceability.
• Availability is robust in North America and Europe but may be limited or variable in emerging markets.
• Procurement strategies must prioritize authorized distributors, regulatory compliance, and inventory management to ensure seamless access.
• Future market trends suggest increased competition through generics and local manufacturing, which could alter the supply landscape.

FAQs

1. Who are the main manufacturers of EVOMELA?

Evoltra LLC, a subsidiary of Clinigen Group, is the exclusive manufacturer of EVOMELA, with no widely available generic equivalents as of now.

2. How can healthcare providers ensure a reliable supply of EVOMELA?

By engaging with authorized distributors such as Clinigen’s network, verifying supplier credentials, and maintaining strategic inventory levels aligned with demand forecasts.

3. Are there regional differences in EVOMELA availability?

Yes. While the drug is widely accessible in North America and Europe, availability in Asia and other emerging markets depends on regional regulatory approvals and distribution partnerships.

4. What are key regulatory considerations in sourcing EVOMELA?

Procurement must be from licensed and authorized distributors approved by relevant authorities like the FDA or EMA to ensure compliance and product quality.

5. What trends might impact EVOMELA’s supply in the future?

Potential introduction of generic versions, local manufacturing initiatives, and advancements in drug delivery formulations are expected to influence the supply chain landscape.

Sources

1. FDA Drug Approval Database. EVOMELA (melphalan hydrochloride injection).
2. Clinigen Group Corporate Website. Product and distribution information.
3. European Medicines Agency (EMA). EVOMELA regulatory status.
4. Pharmaceutical Supply Chain Reports. Industry insights on specialty drug distribution.
5. Market Analysis Reports. Trends in cytotoxic drug manufacturing and supply.

---

By understanding the manufacturing and distribution framework of EVOMELA, healthcare institutions and procurement professionals can optimize sourcing strategies, mitigate supply risks, and ensure uninterrupted patient care.